Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BA 1301

Next Previous
Drug Profile

BA 1301

Alternative Names: BA-1301; Claudin 18.2 ADC - Shandong Boan Biotechnology; PR-301

Latest Information Update: 21 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Boan Biotechnology
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Jan 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in China (IV) (NCT06927349) (Shandong Boan Biotechnology pipeline, August 2023)
  • 09 Jan 2023 Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approves IND application for BA 1301 in solid tumours
  • 09 Jan 2023 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical studies in cancer released by Shandong Boan Biotechnology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top